Tell me again how a company with the first entirely new class of antibiotic since 1987 is worth only 160.45 million market cap.
Not to mention Kevetrin, Prurisol, and Brilacidin-OM (and soon, Bril-UP) in clinical trials.
Absurd, isn't it?
Just talked myself into buying more.
(0)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
-
-
-
-
-
-
-